Answers are grounded in this paper and cite their sources.
Lineage plasticity allows tumor cells to shift their differentiation state during metastatic progression and treatment. Genomic profiling identifies driver alterations and clonal relationships but does not fully characterize the lineage programs expressed by metastatic lesions. This review examines the complementary role of transcriptomic profiling and histopathology in assessing changes in tumor identity, with emphasis on colorectal, pancreatic, prostate, and lung cancers. We discuss studies of lineage transformation, intermediate cellular states, and loss of lineage fidelity, and their relationship to metastatic progression and therapeutic resistance. Bulk, single-cell, single-nucleus, and spatial transcriptomic approaches provide information on malignant-cell differentiation, intratumoral heterogeneity, and microenvironmental context. Integrating these findings with morphology, immunohistochemistry, and genomic analysis may support the development of biomarkers that characterize metastatic cell states and identify programs associated with resistance. By synthesizing these findings, this review aims to clarify how RNA profiling may complement genomic and histopathological assessment of metastatic tumor identity. It also explores how lineage-associated programs could inform diagnostic biomarkers and therapeutic strategies, including modification of plastic states or targeting of their acquired dependencies. The review discusses the analytical and clinical evaluation needed to connect these biological findings with the assessment of metastatic biopsies.
No takes yet. Share an insight, caveat, or question.
Nigro et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: